Obesity in adults with cystic fibrosis following prescription of elexacaftor/tezacaftor/ivacaftor
- 20 June 2026
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (5) , 827-831
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
This publication has 8 references indexed in Scilit:
- Identifying cystic fibrosis programs in the United States with disproportionately disadvantaged patient populations: Methodology and implications for careJournal of Cystic Fibrosis, 2025
- Aging with CF: Characteristics of people with CF aged 40 and older in the United StatesJournal of Cystic Fibrosis, 2024
- Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftorJournal of Cystic Fibrosis, 2024
- Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registryJournal of Cystic Fibrosis, 2022
- Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Making Neighborhood-Disadvantage Metrics Accessible — The Neighborhood AtlasNew England Journal of Medicine, 2018
- The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease RegistryAnnals of the American Thoracic Society, 2016